

## 2019-nCoV Spike protein S1 (A222V)

Catalog No: C19S1-G233H

Novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world since 2020. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization.

- A variant of SARS-CoV-2 carrying A222V mutation in the spike protein, also designated as lineage B.1.177, originated in Spain and then spread rapidly across Europe.
- RBD (S477G) (319-541) was expressed in CHO cells using a C-terminal his tag.

### Product Features



Purity determined by  
densitometry




Biologically  
Active



Expressed in  
CHO cells



QA/QC  
Tested



### Competitors



### Target Customers



Biotech companies  
research A222V  
neutralization



Scientists developing  
diagnostic tests



Biopharma companies  
developing anti-SARS cov 2  
therapies



COVID-19  
ELISAs